BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 4, 2003
View Archived Issues
Roxifiban does not activate platelets from healthy volunteers
Read More
Pozen submits MT-100 NDA
Read More
Medivir licenses MIV-150 to Population Council
Read More
Kyorin and Eisai amend Maxalt agreement
Read More
MOR-201 program discontinued in Q2 at MorphoSys
Read More
Oxagen identifies novel diabetes gene
Read More
FDA approval for Rebetol in pediatric hepatitis C
Read More
Probactrix controls HIV-associated diarrhea in clinical trial
Read More
Health Canada grants clearance for initiation of phase II studies of Infecton
Read More
Pfizer returns P-57 rights to Phytopharm
Read More
Strategic review and Q2 results at Shire
Read More
Combination therapies for allergic diseases comprising an anti-IgE antibody and antiallergic agent
Read More
Use of amylin agonists for reducing triglyceride levels
Read More
Adenosine receptor ligands and their use in depression and other disorders
Read More
IGF-I peptides useful in ophthalmology and dermatology
Read More
Bristol-Myers Squibb presents new antiviral compounds
Read More
New nuclear hormone receptor modulators synthesized at BMS
Read More
Camptothecin encapsulated in cationic liposomes targets tumor blood vessels
Read More
LipoRed: a cationic liposome-based neovascular imaging agent
Read More
AVE-8062A: a tumor vasculature targeting agent with promising antitumor activity
Read More
Additional mechanism of action for IGN-311: inhibition of growth factor signaling
Read More
Prous Science announces the addition of Chronic Rhinosinusitis to the Drug R&D Backgrounders
Read More